Compare Pfizer Inc (PFE) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Pfizer Inc trades at $28.16 (market cap $158.56B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.76 (market cap $3.14B). The key difference: Pfizer Inc is far larger — about 50.5× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Pfizer Inc pays a 6.18% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| PFE | SPHD | |
|---|---|---|
Market Cap | $158.56B | $3.14B |
Volume | 44,138,282 | 1,461,349 |
Sector | Health | — |
52-Week High | $29.02 | $53.55 |
52-Week Low | $23.67 | $46.96 |
Typical Hold Time | 158 Days | 125 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
SPHD trades at $48.72 with a 1.1% daily gain, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF's monthly dividend structure provides consistent income, though recent analysis highlights underperformance compared to peers like SCHD over the past decade. Key support sits at $47 with resistance at $49.
The outlook remains cautious given bearish technical signals and competitive pressure from higher-performing dividend ETFs. While monthly dividends appeal to income-focused investors, SPHD's lack of quality screening exposes it to yield traps. Near-term performance depends on market volatility and dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
